Whole-body PDE10A KO inhibits Ang-II and pressure overload-induced cardiac hypertrophy, fibrosis and dysfunction, suggesting that pharmacological targeting of PDE10A might represent a potential strategy for the treatment of cardiac fibrosis and heart failure [98]. This evidence concerns the gene PDE10A and cardiac hypertrophy.